Episode Details
Back to Episodes
Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6
Published 11 months, 1 week ago
Description
Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada today.